March 7th 2023
Acquired resistance to BTK inhibitors is a new and growing challenge in the treatment of CLL and dual resistance to BTK and BCL2 is occurring in more patients, according to Lindsey Roeker, MD.
Acalabrutinib-Based Regimens Continue to Top Obinutuzumab Plus Chemotherapy in Treatment-Naïve CLL
June 4th 2022With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Read More
Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLL
June 2nd 2022John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
Roundtable Discussion: Saba Reviews Testing, Therapies, and Toxicity With Participants
May 29th 2022Nakhle Saba, MD, reviewed testing, treatment, and treatment toxicity in a 71-year-old woman with chronic lymphocytic leukemia with a group of peers during a Targeted Oncology case-based roundtable event.
Read More
Complex R/R CLL Treatment Landscape Braces as Noncovalent Inhibitors Emerge
May 16th 2022Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.
Read More
Activity of Ceralasertib With BTK Inhibition in High-Risk R/R CLL Calls to Further Investigation
May 12th 2022In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.
Read More
Rationale for In-Depth Analysis of BTK Inhibitor Tolerability in CLL
April 29th 2022John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
FDA Approval Application for U2 Regimen in CLL and SLL Voluntarily Withdrawn
April 18th 2022With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.
Read More
New Methods May Make CAR Therapies More Effective for Patients With CLL
March 30th 2022Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells
Read More
Venetoclax Consolidation Is Well Tolerated in Patients with Previously Untreated CLL
March 29th 2022Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.
Read More
ARI-0001 CAR T-Cell Treatment Shows Promise in R/R CLL, Small Study Shows
March 21st 2022Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.
Read More
Awan Compares BTK Inhibition and Other Treatments for a Patient With CLL
February 18th 2022During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.
Read More